ZINC00881524 (ROCK inhibitor) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 497

Clinical Trials

Several clinical trials are evaluating Rho-kinase (ROCK) inhibitors across neurological and ophthalmological indications. An active, non-recruiting Phase 2 trial sponsored by the Technical University of Munich is assessing ROCK inhibition in idiopathic Parkinson's disease. In ophthalmology, a completed Phase 2/3 study by University Hospital Dubrava evaluated topical administration for glaucoma and pseudophakic bullous keratopathy, while an enrolling-by-invitation trial of unspecified phase is investigating treatment outcomes in patients with Fuchs endothelial corneal dystrophy, cataract, and glaucoma.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05931575	ACTIVE_NOT_RECRUITING	Idiopathic Parkinson´s Disease	Technical University of Munich	2023-09-11	PHASE2
NCT06960629	COMPLETED	Pseudophakic Bullous Keratopathy; Glaucoma	University Hospital Dubrava	2025-01-01	PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-30)

Check the ZINC00881524 (ROCK inhibitor) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

ZINC00881524 selectively binds to and inhibits Rho-associated protein kinase (ROCK), preventing the phosphorylation of downstream target proteins such as myosin light chain phosphatase and suppressing actin cytoskeleton reorganization. This inhibition reduces cellular contractility, enhances endothelial cell survival, and promotes tissue remodeling, offering therapeutic relevance for neurodegenerative pathology such as Parkinson's disease as well as ocular disorders like glaucoma and corneal endothelial dystrophies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).